alendronate and Drug Overdose studies

alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.

Drug Overdose: Accidental or deliberate use of a medication or street drug in excess of normal dosage.

Research Excerpts

Excerpt	Relevance	Reference
"Alendronate is commonly used in the treatment of osteoporosis and other bone diseases."	8.88	Laryngeal ulceration and hemoptysis secondary to inadvertent alendronate overdose: case report and review of the literature. ( Bee, J; Hanna, J; Sataloff, RT, 2012)
" We report here the use of oral alendronate for the treatment of hypercalcemia due to vitamin D intoxication in a 7 month-old infant with nephrocalcinosis."	7.73	Oral alendronate therapy for severe vitamin D intoxication of the infant with nephrocalcinosis. ( Atabek, ME; Pirgon, O; Sert, A, 2006)
"Alendronate is commonly used in the treatment of osteoporosis and other bone diseases."	4.88	Laryngeal ulceration and hemoptysis secondary to inadvertent alendronate overdose: case report and review of the literature. ( Bee, J; Hanna, J; Sataloff, RT, 2012)
"In recent years, alendronate, an oral biphosphonate, has been added to therapy of hypercalcemia secondary to vitamin D intoxication in children."	3.74	Intragastric alendronate therapy in two infants with vitamin D intoxication: a new method. ( Caner, I; Doneray, H; Karakelleoglu, C; Ozkan, A; Ozkan, B, 2008)
" We report here the use of oral alendronate for the treatment of hypercalcemia due to vitamin D intoxication in a 7 month-old infant with nephrocalcinosis."	3.73	Oral alendronate therapy for severe vitamin D intoxication of the infant with nephrocalcinosis. ( Atabek, ME; Pirgon, O; Sert, A, 2006)
"Alendronate treatment achieves normocalcemia four times earlier than prednisolone treatment and shortens hospital stay in infants with vitamin D intoxication."	1.38	Comparison of oral alendronate versus prednisolone in treatment of infants with vitamin D intoxication. ( Bereket, A; Bozaykut, A; Guran, T; Paketçi, C; Seren, LP; Sezer, RG, 2012)

Research

Studies (4)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Blood 25 Hydroxyvitamin D (25OHD) Concentrations

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Sezer, RG	1
Guran, T	1
Paketçi, C	1
Seren, LP	1
Bozaykut, A	1
Bereket, A	1
Hanna, J	1
Bee, J	1
Sataloff, RT	1
Atabek, ME	1
Pirgon, O	1
Sert, A	1
Doneray, H	1
Ozkan, B	1
Caner, I	1
Ozkan, A	1
Karakelleoglu, C	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Prevention of Post-Cardiac Surgery Vitamin D Deficiency in Children With Congenital Heart Disease: A Pilot Dose Evaluation Randomized Controlled Trial[NCT01838447]	Phase 2	46 participants (Actual)	Interventional	2013-07-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Blood 25OHD will be measured to determine vitamin D deficiency, with a concentration below 50 nmol/L used to define deficiency. A PICU admission blood sample could not be obtained for one patient in the Usual Care Group and one patient in the High Dose Group, thus the total number analyzed differs from the full sample size. (NCT01838447)
Timeframe: 1 day (On admission to the pediatric intensive care unit (PICU) following CHD surgery)

Number of Participants With Hypercalcemia as a Vitamin D Related Adverse Event

Intervention	nmol/L (Mean)
Usual Care Group	34.8
High Dose Group	52.0

Hypercalcemia will be defined as an ionized calcium level above 1.40 mmol/L; or above 1.45 mmol/L for children under 8 weeks. Hypercalcemia will be evaluated in blood collected immediately before CHD surgery and throughout the post-operative course (measurements are standard of care). (NCT01838447)
Timeframe: Immediately before surgery, on admission to the PICU following CHD surgery, and on post-operative days 1,3,5 & 10

Post-operative PICU Catecholamine Requirements

Intervention	No. participants with hypercalcemia (Number)
Usual Care Group	0
High Dose Group	0

Primarily, post-operative catecholamine requirements during the PICU admission will be evaluated as a dichotomous variable (yes/no). If a difference is noted in the primary analysis, inotrope requirements will be determined using the inotrope score, evaluated as the maximum score and in a time to event approach (off all inotropes, score of zero) (NCT01838447)
Timeframe: At any point between PICU admission and discharge, an average length of 5-7 days and not longer than 60 days

Number of Participants With Hypercalciuria

Intervention	Participants (Count of Participants)
Usual Care Group	15
High Dose Group	11

Hypercalciuria will be identified using calcium:creatinine ratios defined using age-specific norms and thresholds. (NCT01838447)
Timeframe: Immediately before surgery, on admission to the PICU following CHD surgery, and on the first post-operative day

Article	Year
Comparison of oral alendronate versus prednisolone in treatment of infants with vitamin D intoxication. Acta paediatrica (Oslo, Norway : 1992), 2012, Volume: 101, Issue:3 Topics: Administration, Oral; Alendronate; Anti-Inflammatory Agents; Bone Density Conservation Agents; Drug	2012
Oral alendronate therapy for severe vitamin D intoxication of the infant with nephrocalcinosis. Journal of pediatric endocrinology & metabolism : JPEM, 2006, Volume: 19, Issue:2 Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Drug Overdose; Female; Humans;	2006
Intragastric alendronate therapy in two infants with vitamin D intoxication: a new method. Clinical toxicology (Philadelphia, Pa.), 2008, Volume: 46, Issue:4 Topics: Alendronate; Bone Density Conservation Agents; Drug Overdose; Female; Humans; Hypercalcemia; Infant;	2008

alendronate and Drug Overdose